<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02123407</url>
  </required_header>
  <id_info>
    <org_study_id>CA2014001</org_study_id>
    <nct_id>NCT02123407</nct_id>
  </id_info>
  <brief_title>Clinical Study on the Harvesting Lymph Nodes With Carbon Nanoparticles for Advanced Gastric Cancer</brief_title>
  <official_title>Clinical Study on the Harvesting Lymph Nodes With Carbon Nanoparticles for Advanced Gastric Cancer：a Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carbon Nanoparticles (CNP),with a mean size of 150 nm,can be taken up selectively by
      lymphatics after injection into the tissue and draining regional lymph nodes are thereby
      colored black,which may provide surgeons the guidance to lymph node dissection and help them
      harvest lymph nodes after surgery,especially some small ones. but there was insufficient
      evidence to justify its efficacy for those purposes.Therefore,the investigators carried out a
      prospective randomized controlled trial on lymph node vital staining for lymph node
      dissection and harvesting in advanced gastric cancer to test this idea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carbon Nanoparticles (CNP),with a mean size of 150 nm,can be taken up selectively by
      lymphatics after injection into the tissue and draining regional lymph nodes are thereby
      colored black,which may provide surgeons the guidance to lymph node dissection and help them
      harvest lymph nodes after surgery,especially some small ones. but there was insufficient
      evidence to justify its efficacy for those purposes.Therefore,the investigators carried out a
      prospective randomized controlled trial on lymph node vital staining for lymph node
      dissection and harvesting in advanced gastric cancer to test this idea.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the number of harvested lymph nodes</measure>
    <time_frame>1 day after operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the diameter of harvested lymph nodes</measure>
    <time_frame>1 day after operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Carbon Nanoparticles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carbon Nanoparticles could be used in this arm.The drug is injected into the subserosa of stomach.Injections of 1.0 ml of Carbon Nanoparticles (0.2 ml in each cardinal point adjacent to the lesion) will be performed about 10 minutes before surgery.Then,gastrectomy with D2 dissection will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastrectomy with D2 dissection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gastrectomy with D2 dissection will be performed in the control arm,no Carbon Nanoparticles or other coloring materials used</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbon Nanoparticles</intervention_name>
    <description>Carbon Nanoparticles will be injected into the subserosa of stomach around the tumor.Gastrectomy with D2 dissection will be performed after the injection.</description>
    <arm_group_label>Carbon Nanoparticles</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastrectomy with D2 dissection</intervention_name>
    <description>In the control arm,Gastrectomy with D2 dissection will be performed directly,without any coloring materials.</description>
    <arm_group_label>Gastrectomy with D2 dissection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically and CT confirmed resectable advanced gastric cancer

          -  No prior treatment

          -  No metastases

        Exclusion Criteria:

          -  Having allergic reaction

          -  Pregnant

          -  R0 resection is not achieved by gastrectomy with D2 lymphadenectomy according to
             Japanese gastric cancer treatment guidelines 2010 (ver. 3)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiafu Ji, master</last_name>
    <phone>86-10-88196048</phone>
    <email>dr.jijiafu@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University School of Oncology</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiafu Ji, master</last_name>
      <phone>86-10-88196048</phone>
      <email>dr.jijiafu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jiafu Ji, master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K; Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008 Jul 31;359(5):453-62. doi: 10.1056/NEJMoa0707035.</citation>
    <PMID>18669424</PMID>
  </reference>
  <reference>
    <citation>Catarci M, Guadagni S, Zaraca F, Pistoia MA, Mastracchio A, Trecca A, Ruco L, Carboni M. Prospective randomized evaluation of preoperative endoscopic vital staining using CH-40 for lymph node dissection in gastric cancer. Ann Surg Oncol. 1998 Oct-Nov;5(7):580-4.</citation>
    <PMID>9831104</PMID>
  </reference>
  <reference>
    <citation>Okamoto K, Sawai K, Minato H, Yada H, Shirasu M, Sakakura C, Otsuji E, Kitamura K, Taniguchi H, Hagiwara A, Yamaguchi T, Takahashi T. Number and anatomical extent of lymph node metastases in gastric cancer: analysis using intra-lymph node injection of activated carbon particles (CH40). Jpn J Clin Oncol. 1999 Feb;29(2):74-7.</citation>
    <PMID>10089947</PMID>
  </reference>
  <reference>
    <citation>Siewert JR, Kestlmeier R, Busch R, Böttcher K, Roder JD, Müller J, Fellbaum C, Höfler H. Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases. Br J Surg. 1996 Aug;83(8):1144-7.</citation>
    <PMID>8869330</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2014</study_first_submitted>
  <study_first_submitted_qc>April 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2014</study_first_posted>
  <last_update_submitted>April 23, 2014</last_update_submitted>
  <last_update_submitted_qc>April 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Ziyu Li</investigator_full_name>
    <investigator_title>Peking University</investigator_title>
  </responsible_party>
  <keyword>Advanced Gastric Cancer</keyword>
  <keyword>Carbon Nanoparticles</keyword>
  <keyword>Lymph Nodes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

